CIK 0000882796
- Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 621413174
- Phone
- +1 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-03-12 | ASELAGE STEVE Director | Purchase | +2,000 | $8.30 | $17K | 2,000 |
| 2019-01-31 | Babu Yarlagadda S Senior VP - Drug Discovery | Option exercise | +19,686 | $1.20 | $24K | 127,786 |
| 2019-01-31 | Babu Yarlagadda S Senior VP - Drug Discovery | Shares withheld for taxes | −7,702 | $8.68 | $67K | 120,084 |
| 2019-01-31 | Babu Yarlagadda S Senior VP - Drug Discovery | Option exercise | +12,188 | $1.20 | $15K | 132,272 |
| 2019-01-31 | Babu Yarlagadda S Senior VP - Drug Discovery | Shares withheld for taxes | −1,685 | $8.68 | $15K | 130,587 |
| 2019-01-31 | Babu Yarlagadda S Senior VP - Drug Discovery | Option exercise · Non-Qualified Stock Option | −19,686 | 0 | ||
| 2019-01-31 | Babu Yarlagadda S Senior VP - Drug Discovery | Option exercise · Emp. Stock Option (Right to Buy) | −12,188 | 0 | ||
| 2019-01-28 | STAAB THOMAS R II Senior Vice President and CFO | Option exercise | +5,000 | $5.45 | $27K | 133,426 |
| 2019-01-28 | STAAB THOMAS R II Senior Vice President and CFO | Sale | −5,000 | $9.85 | $49K | 128,426 |
| 2019-01-28 | STAAB THOMAS R II Senior Vice President and CFO | Option exercise · Emp. Stock Option (Right to Buy) | −5,000 | 7,000 | ||
| 2019-01-28 | Powell Lynne Senior VP - CCO | Option exercise | +4,000 | $3.22 | $13K | 4,000 |
| 2019-01-28 | Powell Lynne Senior VP - CCO | Sale | −4,000 | $9.88 | $40K | 0 |
| 2019-01-28 | Powell Lynne Senior VP - CCO | Option exercise | +2,000 | $3.22 | $6K | 2,000 |
| 2019-01-28 | Powell Lynne Senior VP - CCO | Sale | −2,000 | $9.91 | $20K | 0 |
| 2019-01-28 | Powell Lynne Senior VP - CCO | Option exercise · Emp. Stock Option (Right to Buy) | −4,000 | 81,427 | ||
| 2019-01-28 | Powell Lynne Senior VP - CCO | Option exercise · Emp. Stock Option (Right to Buy) | −2,000 | 79,427 | ||
| 2019-01-25 | Powell Lynne Senior VP - CCO | Option exercise | +6,000 | $3.22 | $19K | 6,000 |
| 2019-01-25 | Powell Lynne Senior VP - CCO | Sale | −6,000 | $9.60 | $58K | 0 |
| 2019-01-25 | Powell Lynne Senior VP - CCO | Option exercise · Emp. Stock Option (Right to Buy) | −6,000 | 85,427 | ||
| 2019-01-18 | Powell Lynne Senior VP - CCO | Option exercise | +2,000 | $3.22 | $6K | 2,000 |
Page 30 of 38 · 750 trades